Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (NYSE: LLY) stock defied ... On the higher-profile GLP-1 diet drug news, Lilly cut the monthly, four-dose price of: 5 mg Zepbound to $349 per month, and 5 mg, 7.5 mg, and 10 mg Zepbound ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its ... had allowed for alternatives to be made, sending the stock of telehealth provider Hims & Hers Health Inc ...

Shares of the behemoth drug company trade at more than 70 times earnings. It isn't a cheap buy, but given its strong growth prospects, a premium is justifiable. Lilly could obtain approval for a ...

Eli Lilly (LLY) closed the latest trading day at $822.27, indicating a -0.22% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.49%. Elsewhere, the Dow lost ...

Eli Lilly (NYSE:LLY) announced Tuesday it expanded its weight loss drug offerings, launching new 7.5 mg and 10 mg single-dose vial formats of its popular weight loss therapy Zepbound (tirzepatide ...

Eli Lilly and Novo Nordisk currently dominate the market for the new class of GLP-1 receptor agonist ... both for $499 a month. The drug giant (LLY) is also reducing the price of its 2.5-milligram ...